title: Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction.
abstract: This study compared the safety of formoterol (Oxis Turbuhaler; 90 microg delivered dose; 120 microg metered dose) with terbutaline (Bricanyl Turbuhaler; 10 mg), in patients with acute bronchoconstriction. Forty-eight patients (31 females) with a mean age of 45 yrs, were randomized into two parallel groups (double-blind design). Mean baseline forced expiratory volume in one second (FEV1) was 0.98 L (33% of predicted normal). Study drugs were administered on six occasions during 3 h (formoterol 4.5 microg or terbutaline 0.5 mg x inhalation(-1), 20 inhalations). Patients received intravenous prednisolone after 1.5 h and oxygen during the first 3 h. Pulse rate, serum potassium, 12-lead electrocardiogram (ECG), Holter ECG, arterial blood gases and FEV1 were assessed during 12 h after the first dose. Four patients (one formoterol, three terbutaline) discontinued. The 12-h mean values of serum potassium decreased from 4.02 to 3.89 mmol x L(-1) for formoterol and from 4.22 to 3.76 mmol x L(-1) for terbutaline. Mean 12-h pulse rate was significantly (p<0.01) higher in the terbutaline group (101.7 beats per minute (bpm)) than in the formoterol group (93.5 bpm). No individual patient value was considered clinically important or alarming. FEV1 improved in both groups but with no statistically significant difference between treatments. Oxis Turbuhaler (90 microg) was at least as safe and well tolerated as terbutaline (10 mg) [DOSAGE ERROR CORRECTED] in patients with acute bronchoconstriction.
authors.affiliation: Dept of Internal Medicine and Allergology, Wroclaw University of Medicine, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Malolepszy
authors.forename: G
authors.initials: G
authors.lastname: Böszörményi Nagy
authors.forename: O
authors.initials: O
authors.lastname: Selroos
authors.forename: P
authors.initials: P
authors.lastname: Larsso
authors.forename: R
authors.initials: R
authors.lastname: Brander
mesh_terms: D000208:Acute Disease; D000328:Adult; D001982:Bronchial Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003251:Constriction, Pathologic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography; D015716:Electrocardiography, Ambulatory; D004983:Ethanolamines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005541:Forced Expiratory Volume; D000068759:Formoterol Fumarate; D005740:Gases / Q000097:blood; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D011188:Potassium / Q000097:blood; D011674:Pulse; D012449:Safety; D013726:Terbutaline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001993:Bronchodilator Agents; D004983:Ethanolamines; D005740:Gases; D013726:Terbutaline; D011188:Potassium; D000068759:Formoterol Fumarate